Country Notes

In the United States, ibogaine is listed in Schedule I under federal controlled-substances law. The DEA controlled-substances schedule is the practical starting point for a federal status check; state rules and professional regulation can add further layers.

A Schedule I listing does not erase the possibility of tightly regulated scientific work, but it means research is subject to federal controls rather than being a general clinical pathway. The legal treatment of iboga-containing plant material, extracts, and purified alkaloid should be read against the precise wording of the applicable law and schedule.

Mexico is often described in public discussion as a destination where ibogaine is available, yet availability does not itself establish a single nationwide legal conclusion. A careful review needs to separate drug-control rules, import and customs questions, product classification, and any applicable health-authority requirements.

The distinction between iboga root preparations and purified ibogaine remains material here as elsewhere. Before relying on a current summary, consult the Mexican federal health regulator’s public guidance and the text of any applicable current legal instrument; this note does not endorse providers or describe ways around the law.

New Zealand has been notable in ibogaine discussions because classification and access questions have been described differently at different points in time. A defensible conclusion should therefore identify the date of the source, the precise substance or preparation addressed, and whether the document concerns medicines, controlled drugs, or professional practice.

The New Zealand legislation database is a useful primary starting point for checking whether a provision has been amended, repealed, or superseded. It is safer to state that a position is under review than to extend an older summary beyond its source date.